Search results
Author(s):
Michele De Bonis
,
Ottavio Alfieri
Added:
3 years ago
Degenerative mitral regurgitation (MR) represents a rather common pathology, affecting 1–2% of the general population. In patients requiring surgery for this disease, mitral valve repair is the standard of care. Whenever feasible it is preferable to prosthetic replacement, as it provides better preservation of left ventricular (LV) function, higher survival, lower rates of thromboembolism and…
View more
Author(s):
Michael Hoebartner
,
Philipp Kiefer
,
Michael Andrew Borger
,
et al
Added:
3 years ago
Mitral valve regurgitation (MR) is frequently induced by degenerative mitral valve (MV) disease and leads to leaflet prolapse. Therefore, valve repair is a well-proven surgical technique with excellent long-term outcomes.1–5 The risk of declining left ventricle (LV) function or LV enlargement and the development of atrial fibrillation or severe pulmonary hypertension due to chronic volume…
View more
Author(s):
Martin Swaans
,
Ben van den Branden
,
Marco Post
,
et al
Added:
3 years ago
In Europe, mitral regurgitation (MR) is the second most common form of valvular heart disease needing surgery.1 Studies have shown that up to 50 % of patients with severe symptomatic MR are not referred to surgery, even if a surgical indication exists.1–3 Reasons for denying surgery include impaired left ventricular ejection fraction, a high operative risk, multiple comorbidities or advanced age…
View more
Author(s):
Ottavio Alfieri
,
Michele De Bonis
Added:
3 years ago
Despite the absence of randomised comparison, it is widely accepted that, when feasible, valve repair is the optimal surgical treatment in patients with severe degenerative mitral regurgitation (MR) due to the well documented advantages of such an approach over valve replacement in terms of perioperative mortality, preservation of postoperative left ventricular (LV) function and long-term…
View more
Ottavio Alfieri
Research Area(s) / Expertise:
Job title: Professor of Cardiac Surgery, and Chief, Department of Cardiac Surgery
Author
Author(s):
Kashish Goel
,
Colin M Barker
,
JoAnn Lindenfeld
Added:
3 years ago
Heart failure (HF) is a growing epidemic, with an estimated 6.2 million adults (≥20 years) affected between 2013 and 2016 in the US.1 The prevalence is increasing and is expected to reach 8 million by 2030.1 Mitral regurgitation (MR) is common in HF patients, especially in those with ischaemia, left ventricular (LV) dysfunction or dilated cardiomyopathy. MR in the absence of structural…
View more
EuroPCR 2021 Wrap-up: Mitral and Tricuspid Therapies
Video Series
Gilbert Tang
Author
Author(s):
Gian Paolo Ussia
,
Marco Barbanti
,
Valeria Cammalleri
,
et al
Added:
3 years ago
Author(s):
Enoch Akowuah
Added:
1 year ago
ACC.23/WCC—DrEnoch Akowuah (James Cook University Hospital, UK) joins us to share the findings of the UK Mini-Mitral trial (National Institute of Health Research).
This study is a multicentre, expertise-based randomised controlled trial that aimed to compare the safety and effectiveness of a minimally-invasive thoracotomy compared to conventional sternotomy in treating patients with degenerative…
View more